Early Celecoxib Use in Spontaneous Intracerebral Hemorrhage is Associated with Reduced Mortality
- 15-05-2024
- Celecoxib
- Original work
Published in:
- Authors
- Bao Y. Sciscent
- David R. Hallan
- Debarati Bhanja
- Jacob Staub
- Derek Crossman
- Elias B. Rizk
- J. Christopher Zacko
- Haejoe Park
- Sprague W. Hazard
- Published in
- Neurocritical Care | Issue 3/2024
Abstract
Background
Hemorrhagic strokes constitute 10–15% of all strokes and have the worst mortality and morbidity of all subtypes. Mortality and morbidity of spontaneous intracerebral hemorrhage (sICH) are often secondary to the effects of inflammation, brain edema, and swelling. Studies have shown that celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, reduces perihematomal edema formation and inflammation. This study aimed to examine the impact of celecoxib on sICH outcomes.
Methods
TriNetX, a multi-institutional research database, was retrospectively queried to identify patients with sICH. Outcomes in patients who received celecoxib within 5 days (cohort 1) were analyzed and compared to those in patients who did not receive celecoxib (cohort 2). The primary end point was mortality within 1 year of sICH. Secondary end points included ventilator dependence, tracheostomy, percutaneous endoscopic gastrostomy tube placement, craniotomy, deep venous thrombosis, pulmonary embolism, ischemic stroke, transient ischemia attack, myocardial infarction, and seizures. Further analysis was performed to assess these outcomes for patients treated with ibuprofen, a nonselective COX inhibitor.
Results
After propensity score matching, 833 patients were identified in each cohort based on celecoxib use. Mortality at 1 year was significantly reduced in patients with sICH receiving celecoxib compared to those who did not (13.33% vs. 17.77%; p = 0.0124). Risks of ventilator dependence, tracheostomy, percutaneous endoscopic gastrostomy tube placement, craniotomy, deep venous thrombosis, pulmonary embolism, ischemic stroke, transient ischemia attack, myocardial infarction, and seizures were not significantly increased in patients who received celecoxib within 5 days of sICH compared to those who did not receive celecoxib. There was no significant difference in mortality between patients based on ibuprofen administration.
Conclusions
There exists a growing interest in using COX-2 as a potential target strategy for neuroprotection in patients with sICH, with some evidence of a mortality benefit in small cohort studies. This study shows that early celecoxib use is associated with decreased mortality in patients with sICH.
Advertisement
- Title
- Early Celecoxib Use in Spontaneous Intracerebral Hemorrhage is Associated with Reduced Mortality
- Authors
-
Bao Y. Sciscent
David R. Hallan
Debarati Bhanja
Jacob Staub
Derek Crossman
Elias B. Rizk
J. Christopher Zacko
Haejoe Park
Sprague W. Hazard
- Publication date
- 15-05-2024
- Publisher
- Springer US
- Published in
-
Neurocritical Care / Issue 3/2024
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961 - DOI
- https://doi.org/10.1007/s12028-024-01996-2
This content is only visible if you are logged in and have the appropriate permissions.
